ALT An illustrated diagram from the Review Article "Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead" that shows culture-based and molecular-based antimicrobial-susceptibility testing for H. pylori.

ALT Four panels show the changes from baseline to week 80 in the apnea–hypopnea index (AHI, the number of apneas and hypopneas per hour of sleep) in TRIUMPH-1-OSA (Panel A) and TRIUMPH-2-OSA (Panel C) and the percent changes in body weight from baseline to week 80 in TRIUMPH-1-OSA (Panel B) and TRIUMPH-2-OSA (Panel D).

ALT Four panels show percent changes in other OSA measures (hybrid-treatment estimand). Panels A and B show percent changes at week 80 in the AHI and the sleep apnea–specific hypoxic burden (SASHB, a measure calculated from a polysomnogram that encapsulates the frequency, duration, and depth of respiratory event–related oxygen desaturation) in TRIUMPH-1-OSA (Panel A) and TRIUMPH-2-OSA (Panel B). Panels C and D show the percentage of participants at week 80 with a 50% or greater decrease in AHI or an AHI of less than 5 or 5 to 14 events per hour with a score of 10 or lower on the Epworth Sleepiness Scale (ESS) in TRIUMPH-1-OSA (Panel C) and TRIUMPH-2-OSA (Panel D).

ALT An illustrated diagram shows the pathogenesis of H. pylori infection. Includes sections on colonization, immune evasion, and the immune response, with details on disruption of cell junctions, inflammation, and apoptosis.

ALT This image contains an excerpt from the Research Summary "Obexelimab for IgG4-Related Disease" published in the New England Journal of Medicine. It includes a section with patient statistics: 194 adults, mean age 59, and a male to female ratio of 67% to 33%. To the right is a stylized patient with highlighted areas representing IgG4-related disease. Below are two images comparing treatment groups: Obexelimab (250 mg) and Placebo, each with 97 individuals. A prompt to read the full Research Summary at NEJM.org sits at the bottom.